Method for preparing circular single-strand RNA having precise site-directed modification

By synthesizing single-stranded circular RNA in organisms by using precise assembly and enzyme ligation methods, and site modification is achieved using phosphoramidite solid phase synthesis method, the difficulty and inaccurate modification of long-chain RNA in the prior art are solved. Problem, efficient and low-cost single-strand circular RNA preparation is achieved.

WO2024245313A1PCT designated stage expired Publication Date: 2024-12-05BEIJING SUPRACIRC BIOTECHNOLOGY CO LTD +1

Patent Information

Application Number
PCT/CN2024/096188
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-05-29
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The prior art is difficult to accurately synthesize long-chain single-stranded circular RNA in organisms and achieve chemical modifications at specific sites on it, resulting in limited stability and effectiveness of RNA drugs.

Method used

Using a method based on precision assembly, short RNA fragments are ligated through enzymes to form single-stranded circular RNA, and precise positioning and chemical modification of any site is achieved through phosphoramidite solid phase synthesis, and efficient purification is carried out using enzyme cleavage enrichment.

Benefits of technology

It realizes efficient synthesis of single-stranded circular RNA with precise modification at any site, overcomes the problems of high synthesis difficulty and low purity in the prior art, reduces cost and time, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024096188_05122024_PF_FP_ABST
    Figure CN2024096188_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a method for preparing a circular single-strand RNA. According to the method, by designing a first RNA fragment and a first DNA fragment, chemical modification of any precise site of a circular single-strand RNA can be achieved, so that the circular single-strand RNA has higher stability, a better binding capability, improved immunogenicity and the like, and a use of the circular single-strand RNA in the field of biomedicine is effectively broadened. By means of said preparation method, a double-strand assembly formed by complementation of a circular single-strand RNA and a fragmented single-strand nucleic acid chain can be obtained, and a circular single-strand RNA can be obtained simply by carrying out an enzyme digestion reaction on the double-strand assembly, so that the current synthesis steps of the circular single-strand RNA are effectively simplified, and the synthesis efficiency is improved. Thus, the preparation method is suitable for industrial large-scale preparation.
Need to check novelty before this filing date? Find Prior Art

Description

A method for preparing single-stranded circular RNA with precise site-specific modification Technical Field

[0001] The present invention belongs to the fields of molecular biology and synthetic biology. Specifically, the present invention relates to a method for preparing single-stranded circular RNA with precise site modification. Background Art

[0002] In recent years, RNA-based nucleic acid drugs have shown remarkable application potential in biomedical fields such as inherited metabolic diseases, antiviral vaccine preparation, tumor treatment and regenerative medicine. Currently, many studies have reported on infectious disease vaccines and anti-tumor drugs based on mRNA. In addition, small interfering RNA (siRNA)-based [1] , small RNA (microRNA, miRNA) [2] , long non-coding RNA (lncRNA) [3] RNA aptamer [4] and Ribozyme [5] The therapeutic technology of RNA molecules is also developing rapidly, and the application of RNA drugs in biology is receiving more and more attention.

[0003] In addition, due to their physical and chemical properties, RNA drugs are often very easily degraded by nucleases in the body, and have problems such as poor stability, short duration of efficacy, and poor bioavailability.

[0004] Single-stranded circular RNA (circRNA) has no free ends and is therefore not easily digested by RNA exonucleases, showing higher stability. In addition, large-sized circRNAs have a molecular weight higher than the glomerular filtration threshold, which gives them a longer in vivo circulation time and better bioavailability. Currently, some single-stranded circular RNAs have been developed as miRNA sponges, representing a functional and inexpensive alternative miRNA sponge drug. [6] Therefore, with the continuous promotion of single-stranded circular RNA drugs in biological research, drug development and clinical application, higher requirements are also placed on the preparation methods of single-stranded circular RNA.

[0005] Currently, unmodified RNA has shown rich application prospects in the field of biomedicine. However, the safety issues caused by its activation of innate immune responses in biological systems have greatly limited the actual therapeutic application of unmodified RNA. Studies have shown that the introduction of chemical modifications (such as base modification, ribose modification and phosphate backbone modification) can inhibit RNA from being recognized by nucleases and the immune system, thereby improving its stability in the body, reducing innate immune activation, and at the same time improving its ability to bind to target RNA molecules, making it exhibit more excellent therapeutic effects.

[0006] Currently, the synthesis methods of single-stranded circular RNA mainly include reverse splicing-based transcription [7] and long single-stranded RNA-based circular ligation [8] Among them, the use of plasmids or viral vectors with flanking introns carrying reverse splicing signals to transcribe and express single-stranded circular RNA is more widely used. When a vector with a reverse splicing signal is transcribed, the sequence of the reverse splicing signal will hydrolyze and attack the front signal, and will not be transcribed sequentially. The connection between the front and back ends leads to the formation of circular RNA. However, the reverse splicing efficiency of this construction vector is limited, which will lead to the transcription of unspliced ​​and reverse-spliced ​​RNA impurity molecules. At the same time, the construction of the vector requires a very long inherent sequence to ensure the reverse splicing, and the length limitation of the vector itself also brings difficulties to the synthesis of target single-stranded circular RNA with large molecular weight. Another method is to first use T7 RNA polymerase to transcribe in vitro to produce single-stranded RNA, and then use T4 RNA ligase or chemical methods to circularize the single-stranded RNA head to tail. Low circularization efficiency and purification methods are still limiting factors for its application. At the same time, the double-stranded RNA produced by in vitro transcription may cause innate immune response.

[0007] In addition, both methods require the construction of DNA templates or plasmids, which brings more steps to the synthesis of single-stranded circular RNA. At the same time, neither of these two methods can currently accurately introduce chemical modifications to the synthesized circular RNA, and chemical modification is crucial to its stability and effectiveness. The circular splicing method cannot be chemically modified, and the in vitro transcription method is highly dependent on RNA polymerase, and can only achieve random insertion of modified bases in the sequence through enzyme engineering, adding a certain proportion of modified base monomers, etc. However, this method of adding modified bases during in vitro transcription cannot achieve precise modification of specific sites due to the non-selectivity of the enzyme to the site, but can only achieve control of the overall modification ratio. The RNA sequence containing modified bases obtained in this way is a mixture of multiple sequences at the molecular level, which has hindered its in-depth study of the chemical modification effect on specific sites in biomedicine.

[0008] Summary of the Invention

[0009] Given the limitations of existing technology, the synthesis of single-stranded circular RNA containing modified groups at specific sites and single-stranded circular RNA with a length greater than 200 nt are both huge challenges in the current synthesis field, and the simple and convenient synthesis of these target products is even more difficult to achieve.

[0010] The present invention provides a method for preparing single-stranded circular RNA. Based on the precise assembly of a first RNA fragment and the subsequent ligation process, single-stranded circular RNA with any length (e.g., a length greater than 200 nt) and any sequence can be synthesized simply and conveniently.

[0011] Since the first RNA fragment is short, those skilled in the art can synthesize it by phosphoramidite solid phase method. 9 Conventional methods in the art such as these allow the first RNA fragment to be chemically modified at any site with precise positioning, thereby allowing the final synthesized single-stranded circular RNA to be modified at precisely that site. The method of the present invention can prepare single-stranded circular RNA with precise modification at any site, overcoming the current technical obstacle of being unable to synthesize long-chain RNA with precise site modification, and has the advantages of low synthesis difficulty, high accuracy, and low cost.

[0012] At the same time, the method of the present invention can utilize enzyme digestion and enrichment to quickly purify the product, thereby reducing the economic and time costs of preparation.

[0013] In summary, the method of the present invention utilizes the principles of nucleic acid assembly to control the assembly structure of short-chain RNAs, and uses an enzymatic ligation method to efficiently connect short-chain RNA fragments to form single-stranded circular RNA molecules. Enzymatic digestion and sedimentation methods are then used for efficient purification, increasing the yield of the target product.

[0014] In some aspects, the present invention provides a nucleic acid assembly that can be used to prepare long RNAs with precisely targeted chemical modifications at any site.

[0015] In some embodiments, the nucleic acid combination comprises at least two first RNA segments, at least two first DNA segments, and optionally, at least one second DNA segment. The first RNA segments are used to connect to form a long single-stranded RNA. Preferably, in some embodiments, the number of the first RNA segments is at most 20, preferably 4-10, and more preferably 4-8. Preferably, in some embodiments, the number of the second DNA segments is one less than the number of the first RNA segments. Preferably, in some embodiments, the nucleic acid combination comprises one second DNA segment.

[0016] In some embodiments, the first RNA segment is a 5' phosphorylated first RNA segment.

[0017] In some embodiments, the first RNA segment comprises a 5' spacer, a functional sequence region, and a 3' spacer. Preferably, in some embodiments, the first RNA segment comprises a 5' spacer, a functional sequence region, and a 3' spacer from the 5' end to the 3' end.

[0018] In some embodiments, the 5' spacer sequence of each first RNA segment is different, the 3' spacer sequence of each first RNA segment is different, and / or the 5' spacer sequence and 3' spacer sequence of the same first RNA segment are different. Preferably, in some embodiments, the 5' spacer sequence of each first RNA segment is different, the 3' spacer sequence of each first RNA segment is different, and the 5' spacer sequence and 3' spacer sequence of the same first RNA segment are different. In some embodiments, the length of the 5' spacer and / or the 3' spacer is 8-20 nt.

[0019] In some embodiments, the functional sequence region is a sequence that interacts with miRNA, a short RNA of 15-50 nt in length, mRNA, pre-mRNA, lncRNA, circRNA, DNA or protein. Preferably, in some embodiments, the functional sequence region is a sequence that interacts with miRNA and / or siRNA.

[0020] In some embodiments, the first RNA segment is 16-100 nt in length.

[0021] In some embodiments, the first DNA fragment comprises a sequence that is complementary to the 5' spacer region of the first RNA fragment and a sequence that is complementary to the 3' spacer region of another first RNA fragment. Preferably, in some embodiments, the first DNA fragment comprises a sequence that is fully or partially complementary to the 5' spacer region of the first RNA fragment and a sequence that is fully or partially complementary to the 3' spacer region of another first RNA fragment.

[0022] In some embodiments, the first DNA fragment is 16-40 nt in length.

[0023] In some embodiments, the second DNA fragment comprises a sequence that is fully or partially complementary to the sequence at the 5' end of the long single-stranded RNA, and a sequence that is fully or partially complementary to the sequence at the 3' end of the long single-stranded RNA. Preferably, in some embodiments, the second DNA fragment comprises a sequence that is complementary to a 4-35 nt sequence at the 5' end of the long single-stranded RNA, and a sequence that is complementary to a 4-35 nt sequence at the 3' end of the long single-stranded RNA.

[0024] In some embodiments, the second DNA fragment is 32-80 nt in length, preferably 64 nt in length.

[0025] In some aspects, the present invention provides a method for preparing single-stranded circular RNA, comprising the following steps:

[0026] Step (1): connecting the first RNA fragments to obtain a long single-stranded RNA;

[0027] Step (2): Connect two long single-stranded RNAs to obtain single-stranded circular RNA.

[0028] In some embodiments, the first RNA fragment is 5'-phosphorylated before step (1), ie, a phosphate group is added to the 5' end of the first RNA fragment.

[0029] In some embodiments, step (1) comprises the following steps:

[0030] Step (1.1): mixing the first RNA fragment and the first DNA fragment of the present application and then annealing;

[0031] Step (1.2): connecting the product of step (1.1);

[0032] Optionally, in some embodiments, step (1) includes step (1.3): purifying the product of step (1.2).

[0033] In some embodiments, step (1.2) uses T4 RNA ligase for ligation.

[0034] In some embodiments, step (1.3) comprises an ultrafiltration step. Optionally, in some embodiments, purification is performed using an ultrafiltration tube or using size-selective magnetic beads.

[0035] In some embodiments, step (2) comprises the following steps:

[0036] Step (2.1): mixing the product of step (1) with the second DNA fragment and then annealing;

[0037] Step (2.2): connecting the product of step (2.1);

[0038] Optionally, in some embodiments, step (2) includes step (2.3): purifying the product of step (2.2).

[0039] In some embodiments, step (2.2) uses a circularizing ligase for ligation.

[0040] In some embodiments, step (2.3) comprises the following steps:

[0041] Step (2.3.1): Add DNase I for enzyme digestion;

[0042] Step (2.3.2): Add RNase R for enzyme digestion; and / or

[0043] Step (2.3.3): Purification, optionally, in some embodiments, is performed using ethanol and using an ultrafiltration method.

[0044] In some embodiments, the length of the single-stranded circular RNA is 180 nt-1000 nt. Preferably, in some embodiments, the length of the single-stranded circular RNA is 240 nt-1000 nt.

[0045] In some aspects, the present invention provides a use of a nucleic acid combination of the present invention in preparing a single-stranded circular RNA. The single-stranded circular RNA can contain any RNA modification (such as any RNA modification of interest) at any site.

[0046] In some aspects, the present invention provides a single-stranded circular RNA of the present invention, and its use in treating, preventing or diagnosing a disease or in preparing a drug or diagnostic or detection reagent for treating or preventing a disease.

[0047] In some embodiments, the single-stranded circular RNA regulates the function of a target nucleic acid in a subject. Preferably, in some embodiments, the single-stranded circular RNA regulates the function of pre-mRNA, mRNA, miRNA, lncRNA, circRNA, and tRNA in a subject.

[0048] In some embodiments, the single-stranded circular RNA can serve as a sponge for RNA drugs. Preferably, in some embodiments, the RNA drug is a miRNA and / or siRNA drug.

[0049] In some aspects, the present invention provides a use of a second DNA fragment for preparing a single-stranded circular RNA. The second DNA fragment comprises sequences complementary to the sequences at the 5' end and the 3' end of the aforementioned long single-stranded RNA.

[0050] In some embodiments, the 5'-end and 3'-end sequences of the second DNA fragment contain sequences that are completely or partially complementary to the 5'-end sequence of the aforementioned long single-stranded RNA.

[0051] In some embodiments, the non-5'-non-3' sequence of the second DNA fragment comprises a sequence that is completely or partially complementary to the 3' sequence of the aforementioned long single-stranded RNA.

[0052] The method of the present invention can be used as a platform for preparing single-stranded circular RNA and can be used to prepare single-stranded circular RNA of any length and with any precise RNA modification at any site. The preparation of single-stranded circular RNA by the method of the present invention has the following advantages:

[0053] (1) Ability to prepare single-stranded circular RNA with any RNA modification of interest at any site, i.e., ability to achieve precise modification of single-stranded circular RNA;

[0054] (2) The length and sequence of the prepared single-stranded circular RNA are not limited, that is, single-stranded circular RNA of any length (e.g., longer than 200 nt) or sequence can be prepared;

[0055] (3) The prepared single-stranded circular RNA has high purity, high yield, and high efficiency, significantly reducing the amount of impurity molecules produced by traditional methods, while also being low in cost and suitable for industrial production;

[0056] (4) Ability to prepare symmetrical single-stranded circular RNA; which can play a better role as a miRNA sponge, for example;

[0057] (5) The preparation process is simple and can be prepared by a one-pot synthesis method. BRIEF DESCRIPTION OF THE DRAWINGS

[0058] Figure 1 shows a schematic diagram of the synthesis of single-stranded circular RNA with precise site chemical modification;

[0059] FIG2 shows the synthesis and purification characterization of unmodified 254 nt single-stranded circular RNA;

[0060] FIG3 shows the cell transfection and anti-miRNA effect of unmodified 254nt single-stranded circular RNA;

[0061] FIG4 shows a schematic diagram of the sequence of a 254nt single-stranded circular RNA modified with a precise site Ψ (pseudouridine);

[0062] FIG5 shows the cell transfection and anti-miRNA effect of a 254nt single-stranded circular RNA modified with a precise site Ψ (pseudouridine);

[0063] FIG6 shows the immunogenicity characterization of unmodified and precisely site-modified 254 nt single-stranded circular RNA. DETAILED DESCRIPTION

[0064] Listed below are definitions of various terms used to describe the nucleic acid combinations and compositions disclosed herein. These definitions apply to the terms used throughout this specification and claims, except where otherwise limited in specific cases, and these terms are used either individually or as part of a larger group.

[0065] As used herein, the terms "optional" and "optionally" include both selection and non-selection. For example, "optionally modified" includes both modification and non-modification.

[0066] As used herein, the terms "a," "an," and "the" are generally construed to cover both the singular and the plural.

[0067] The term "include" as used herein means and can be used interchangeably with the phrase "including (but not limited to)". The term "comprising" as used herein means and can be used interchangeably with the phrase "including (but not limited to)". The technical solutions using "include" or "comprising" in this patent can be further limited to "consisting of" or "composed of".

[0068] Throughout this specification, reference to "one embodiment," "some embodiments," "an embodiment," "a specific embodiment," "a related embodiment," "an embodiment," "an additional embodiment," or "a further embodiment," or combinations thereof, means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the aforementioned phrases in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0069] As used herein, "strip", such as "1", refers to one, a type, or a segment of corresponding nucleic acid molecules. For example, "at least two first RNA segments" refers to the nucleic acid combination comprising at least two RNA nucleic acid molecules with different sequences and / or different modifications.

[0070] As used herein, "composition" can be used interchangeably with "combination," "system," and "system," and does not limit the components to being in one product or package. In some embodiments, a "composition" as used herein may refer to a composition in which the corresponding components are in one product or package. In some embodiments, a "composition" may also refer to a composition in which the corresponding components are not in one product or package.

[0071] The prior art cited in this specification is hereby incorporated by reference in its entirety and for all purposes.

[0072] First RNA fragment

[0073] The "first RNA fragment" described herein refers to a single-stranded RNA fragment with a free phosphate group at its 5' end. The present inventors have discovered that the first RNA fragment can be used to form a single-stranded circular RNA using the methods of the present invention. Because the first RNA fragment is relatively short, those skilled in the art can use conventional methods to precisely modify the first RNA fragment at any site, thereby ensuring that the resulting synthesized single-stranded circular RNA has RNA modifications at precisely defined sites. The first RNA fragment herein can be synthesized using any method known in the art.

[0074] There are many types of RNA modifications that can be used in the present invention. All RNA modifications that exist in the art can be used for the purposes of the present invention. RNA modifications that can be used in the present invention include, but are not limited to, base modifications such as m 6 A、Ψ、m 1 A、m 5 A.ms 2 i 6 A.i 6 A、m 3 C、m 5 C、ac 4 C、m 7 G、m2,2G、m 2 G、m 1 G, Q, m 5 U、mcm 5 U、ncm 5 U、ncm 5 Um、D、mcm 5 s 2 U、Inosine(I),hm 5 C.s 4 U.s. 2 U, azobenzene, Cm, Um, Gm, t 6 A、yW、ms 2 t 6 A or its derivatives; ribose modifications include, for example, LNA, 2'-OMe, 3'-OMeU, vmoe, 2'-F or 2'-OBn (2'-O-benzyl group) or their derivatives; phosphodiester bond modifications include, for example, phosphorothioate (PS), nucleotide triphosphate (NTPαS) or its derivatives, etc.

[0075] In some embodiments, the length of the first RNA segment is between 16 and 100 nt. Preferably, in some embodiments, the length of the first RNA segment is 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt, 60 nt, 65 nt, 70 nt, 75 nt, 80 nt, 85 nt, or any integer therebetween. More preferably, in some embodiments, the length of the first RNA segment is 40 nt, 45 nt, 50 nt, 55 nt, 60 nt, 65 nt, 70 nt, 75 nt, 80 nt, 85 nt, or any integer therebetween.

[0076] In some embodiments, the first RNA fragment comprises a 5' spacer, a functional sequence region and a 3' spacer. Preferably, in some embodiments, the first RNA fragment is sequentially a 5' spacer (5'spacer), a functional sequence region and a 3' spacer (3'spacer) from the 5' end to the 3' end. In some embodiments, the length of the 5' spacer and / or the 3' spacer is 8-20nt or any integer therebetween. Preferably, in some embodiments, the length of the 5' spacer and / or the 3' spacer is 10-18nt or any integer therebetween. More preferably, in some embodiments, the length of the 5' spacer and / or the 3' spacer is 13-16nt or any integer therebetween.

[0077] In some embodiments, the functional sequence region is a specific sequence that interacts with miRNA or short-chain RNA (15-50 nt), mRNA, pre-mRNA, lncRNA, circRNA, DNA, protein, etc. Preferably, in some embodiments, the functional sequence region is a specific sequence that interacts with miRNA and / or siRNA.

[0078] In order to realize the different functions of single-stranded circular RNA, such as serving as a miRNA sponge, regulating transcription, localizing proteins, and expressing target genes, those skilled in the art can adjust the sequence and sequence length of the functional sequence region based on the knowledge in the art to realize the above functions.

[0079] The first RNA fragments can be connected according to the method of the present invention to form a long single-stranded RNA. The long single-stranded RNA can serve as an intermediate for synthesizing a single-stranded circular RNA according to the method of the present invention.

[0080] The first RNA segment can be synthesized using any means known in the art, such as solid phase synthesis.

[0081] First DNA fragment

[0082] The "first DNA fragment" described herein is a single-stranded DNA nucleic acid fragment, which can be used to prepare single-stranded circular RNA according to the method of the present invention.

[0083] In some embodiments, the first DNA fragment comprises a sequence that is complementary to the 5' spacer region of the first RNA fragment and a sequence that is complementary to the 3' spacer region of the first RNA fragment. Preferably, in some embodiments, the first DNA fragment comprises a sequence that is fully complementary to the 5' spacer region of the first RNA fragment and a sequence that is fully complementary to the 3' spacer region of the first RNA fragment.

[0084] In some embodiments, the length of the first DNA fragment is 16-40 nt. Preferably, in some embodiments, the length of the first DNA fragment is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nt or any integer therebetween.

[0085] The second DNA fragment

[0086] The "second DNA fragment" described herein is a single-stranded DNA nucleic acid fragment, which can be used to prepare single-stranded circular RNA according to the method of the present invention.

[0087] In some embodiments, the second DNA fragment comprises a sequence that is completely or partially complementary to the sequence at the 5' end of the long single-stranded RNA formed by the first RNA fragment, and a sequence that is completely or partially complementary to the sequence at the 3' end of the long single-stranded RNA formed by the first RNA fragment. In some embodiments, the second DNA fragment comprises a sequence that is complementary to a 4-35 nt sequence at the 5' end of the long single-stranded RNA, and a sequence that is complementary to a 4-35 nt sequence at the 3' end of the long single-stranded RNA.

[0088] The 5' end sequence of a long single-stranded RNA as described herein refers to a nucleic acid sequence extending from the first base at the 5' end of the long single-stranded RNA to a certain length toward the 3' end. In some embodiments, the certain length can be 300 nt, 280 nt, 260 nt, 240 nt, 220 nt, 200 nt, 180 nt, 160 nt, 140 nt, 120 nt, 100 nt, 80 nt, 60 nt, 40 nt, or 20 nt, and is preferably less than 200 nt.

[0089] The 3' end sequence of a long single-stranded RNA as described herein refers to a nucleic acid sequence extending from the first base at the 3' end of the long single-stranded RNA to a certain length toward the 5' end. In some embodiments, the certain length can be 300 nt, 280 nt, 260 nt, 240 nt, 220 nt, 200 nt, 180 nt, 160 nt, 140 nt, 120 nt, 100 nt, 80 nt, 60 nt, 40 nt, or 20 nt, and is preferably less than 200 nt.

[0090] In some embodiments, the length of the second DNA fragment is 32-80 nt, such as 40 nt, 50 nt, 60 nt, 70 nt, 80 nt or any integer therebetween. Preferably, in some embodiments, the length of the second DNA fragment is 64 nt.

[0091] In some embodiments, the 5'-end and 3'-end sequences of the second DNA fragment contain sequences that are completely or partially complementary to the 5'-end sequence of the aforementioned long single-stranded RNA.

[0092] In some embodiments, the non-5'-non-3' sequence of the second DNA fragment comprises a sequence that is completely or partially complementary to the 3' sequence of the aforementioned long single-stranded RNA.

[0093] The 5' end sequence of the second DNA fragment as described herein refers to a nucleic acid sequence extending from the first base at the 5' end of the DNA fragment to a certain length towards the 3' end. In some embodiments, the certain length can be 300 nt, 280 nt, 260 nt, 240 nt, 220 nt, 200 nt, 180 nt, 160 nt, 140 nt, 120 nt, 100 nt, 80 nt, 60 nt, 40 nt, or 20 nt, and is preferably less than 200 nt.

[0094] The 3'-end sequence of the second DNA fragment as described herein refers to a nucleic acid sequence extending from the first base at the 3'-end of the DNA fragment to a certain length toward the 5'-end. In some embodiments, the certain length can be 300 nt, 280 nt, 260 nt, 240 nt, 220 nt, 200 nt, 180 nt, 160 nt, 140 nt, 120 nt, 100 nt, 80 nt, 60 nt, 40 nt, or 20 nt, and is preferably less than 200 nt.

[0095] The non-5'-non-3' sequence of the second DNA fragment described herein refers to a nucleic acid sequence of any length located outside the 5'-end and 3'-end sequences of the DNA fragment.

[0096] Nucleic acid combination

[0097] The present invention provides a nucleic acid combination that can be used to prepare single-stranded circular RNA according to the method of the present invention. The single-stranded circular RNA can have precise positioning chemical modifications at any site, or can be a single-stranded circular RNA of large length (e.g., greater than 200 nt).

[0098] In some embodiments, the first RNA segment is a 5' phosphorylated first RNA segment.

[0099] In some embodiments, the nucleic acid combination comprises at least two first RNA segments, at least two first DNA segments, and optionally, at least one second DNA segment. Preferably, the number of the first RNA segments is 2-20 or any integer therebetween, preferably, the number of the first RNA segments is 4-10, more preferably 4-8, such as 4, 5, 6, 7, or 8.

[0100] In some embodiments, the 5' spacer sequences of different first RNA segments are different. In some embodiments, the 3' spacer sequences of different first RNA segments are different.

[0101] In some embodiments, the functional sequence regions of different first RNA fragments are identical. In some embodiments, the functional sequence regions of different first RNA fragments are not identical. In some embodiments, the functional sequence regions of different first RNA fragments are all different.

[0102] The molar amounts of the different first RNA fragments can be in any ratio. Preferably, in some embodiments, the molar amounts of the different first RNA fragments are the same.

[0103] The molar amounts of the different first DNA fragments can be in any ratio. Preferably, in some embodiments, the molar amounts of the different first DNA fragments are the same.

[0104] The molar amount of the total first RNA fragments (i.e., the sum of the molar amounts of the different first RNA fragments) and the molar amount of the total first DNA fragments (i.e., the sum of the molar amounts of the different first DNA fragments) can be in any ratio. Preferably, in some embodiments, the molar amount of the total first RNA fragments is the same as the molar amount of the total first DNA fragments.

[0105] In some embodiments, the nucleic acid combination herein may further comprise enzymes, buffers and other reagents for preparing single-stranded circular RNA according to the methods herein, and optionally constitute a kit with the enzymes, buffers and other reagents.

[0106] Method for preparing single-stranded circular RNA

[0107] The present invention provides a method for preparing single-stranded circular RNA. The single-stranded circular RNA can carry a precisely located RNA modification at any site. The preparation method comprises the following steps:

[0108] Step (1): connecting the first RNA fragments to obtain a long single-stranded RNA;

[0109] Step (2): Connect two long single-stranded RNAs to obtain single-stranded circular RNA.

[0110] Preferably, in some embodiments, the first RNA fragment and the first DNA fragment in step (1) are in equimolar amounts.

[0111] In some embodiments, the first RNA fragment is 5'-phosphorylated before step (1), ie, a phosphate group is added to the 5' end of the first RNA fragment.

[0112] i. Step (1)

[0113] In some embodiments, step (1) comprises the following steps:

[0114] Step (1.1): mixing the first RNA fragment and the first DNA fragment and then annealing them;

[0115] Step (1.2): connecting the product of step (1.1);

[0116] Optionally, in some embodiments, step (1) further comprises step (1.3): purifying the product of step (1.2).

[0117] In some embodiments, step (1.2) uses T4 RNA ligase for ligation.

[0118] In some embodiments, step (1.3) comprises an ultrafiltration step, optionally performed using an ultrafiltration tube or purification using size-selective magnetic beads.

[0119] ii. Step (2)

[0120] In some embodiments, step (2) comprises the following steps:

[0121] Step (2.1): mixing the product of step (1) with the second DNA fragment and then annealing;

[0122] Step (2.2): connecting the product of step (2.1);

[0123] Optionally, in some embodiments, step (2.3): purifying the product of step (2.2).

[0124] In some embodiments, step (2.2) uses a circular ligase for ligation.

[0125] In some embodiments, step (2.3) comprises the following steps:

[0126] Step (2.3.1): Add DNase I for enzyme digestion;

[0127] Step (2.3.2): Add RNase R for enzyme digestion; and / or

[0128] Step (2.3.3): Purification, optionally, in some embodiments, is performed using ethanol and using an ultrafiltration method.

[0129] The methods for preparing single-stranded circular RNA of the present invention can be used to prepare single-stranded circular RNA of any length. In some embodiments, the length of the single-stranded circular RNA is 180 nt–1000 nt. Preferably, in some embodiments, the length of the single-stranded circular RNA is 240 nt–1000 nt or any integer therebetween.

[0130] An example of a method of preparing a single-stranded circular RNA with precise site chemical modification according to the present invention is as follows, which comprises the following steps:

[0131] Short chain synthesis: multiple first RNA fragments, multiple first DNA fragments and second DNA fragments are synthesized by solid phase synthesis. The multiple first RNA fragments can be recorded as circ-ni, circ-n i+1 、circ-n i+2 、circ-n i+3 , the multiple first DNA fragments can be recorded as DNAm i 、DNAm i+1 、DNAm i+2 、DNAm i+2 The second DNA fragment is recorded as cycle-n i .

[0132] The multiple first RNA fragments are all 5' phosphate-modified RNA fragments, and from the 5' end to the 3' end are a 5' spacer, a functional sequence region and a 3' spacer.

[0133] Among them, the first DNA fragment DNAm i The 5' end sequence is the same as the RNA fragment circ-n i+1 The 5' spacer region of the first DNA fragment is completely complementary to the sequence of i The 3' end sequence of the RNA fragment circ-n i The 3' spacer region is completely complementary to the sequence.

[0134] 1. Annealing step: anneal the multiple first RNA fragments (circ-n i 、circ-n i+1… ) and the first DNA fragment (DNAm i , DNAm i+1… ) are mixed in the same reaction system in equimolar equivalents and annealed to form a double-stranded assembly precursor; wherein, there are connectors between adjacent first RNA fragments and there are connectors between adjacent first DNA fragments; and the connectors between adjacent first RNA fragments and the connectors between adjacent first DNA fragments are staggered.

[0135] 2. Ligation step: The double-stranded assembly after annealing in step 1 is subjected to enzyme ligation treatment (T4 RNA Ligase 2), and each connector is connected to obtain a double-stranded assembly formed by the continuous long single-stranded RNA and the fragmented DNA nucleic acid chain.

[0136] 3. Crude purification step: The long single-stranded RNA system obtained in step 2 is subjected to ultrafiltration for concentration and desalting. In some embodiments, this is performed using an ultrafiltration tube. In some embodiments, this is performed using volume separation magnetic beads.

[0137] 4. Annealing step: Cycle-n the product from step 3 and the second DNA fragment i The equimolar amounts are mixed in the same reaction system and annealed to form an assembly precursor containing a double cross structure.

[0138] The second DNA fragment cycle-n i It can be fully complementary to the 5' end and 3' end 4-35nt part of the long single-stranded RNA formed by connecting the above multiple 5' phosphate-modified RNA fragments, making cycle-n i It forms a double crossover structure with two long single-stranded RNAs.

[0139] 5. Connection step: The assembly in step 4 is treated with circligase to connect all interfaces near the double-cross structure to obtain a double-stranded assembly formed by the complementary long circular single-stranded RNA and the fragmented DNA nucleic acid chain.

[0140] 6. Purification steps:

[0141] A. Enzyme digestion step 1: Treat the product from step 5 with DNase I to completely remove the complementary DNA strand.

[0142] B. Enzyme digestion step 2: Treat the product from step 6A with RNase R to completely remove the linear long single-stranded RNA.

[0143] C. Enrichment: Ethanol precipitation followed by ultrafiltration and salt removal to enrich the target single-stranded circular RNA.

[0144] In some embodiments, according to the method for preparing single-stranded circular RNA of the present invention, the length of the single-stranded circular RNA is 180nt-1000nt, preferably 240nt-1000nt.

[0145] Example

[0146] The embodiments of the present invention will be described in detail below with reference to the examples, but those skilled in the art will appreciate that the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the invention. Where specific conditions are not specified in the examples, the methods were performed according to conventional conditions or the conditions recommended by the manufacturer. Where the manufacturers of the reagents or instruments are not specified, they are all commercially available conventional products.

[0147] The experimental techniques and methods used in this example are conventional unless otherwise specified. For example, in the following examples, where specific conditions are not specified, conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989) or the conditions recommended by the manufacturer are generally followed. Materials and reagents used in the examples were obtained through commercial channels unless otherwise specified.

[0148] Experimental Materials

[0149] The experimental reagent information used in this example is shown in Table 1, the sequence of the first RNA fragment used is shown in Table 2, and the sequence of the first DNA fragment used is shown in Table 3.

[0150] Table 1 Experimental reagent information

[0151] Table 2 Modified first RNA fragment

[0152] Table 3 The first DNA fragment and the second DNA fragment

[0153] The RNA and DNA fragments in the examples were synthesized using a Mermade 12 solid-phase synthesizer. All experimental water was enzyme-free water. All other chemical reagents were of premium grade or higher.

[0154] Example 1: Preparation, characterization and functional verification of unmodified 254nt single-stranded circular RNA

[0155] In the first RNA fragment of the raw material (all 5' phosphate-modified RNA fragments), circ-1 and circ-4 contain sequences complementary to miRNA-21, circ-2 contains a sequence complementary to miRNA-221, and circ-3 contains a sequence complementary to miRNA-195. Therefore, the target single-stranded circular RNA prepared contains 4 sequences complementary to miRNA-21, 2 sequences complementary to miRNA-221, and 2 sequences complementary to miRNA-195, which can fully exert the effect of resisting multiple miRNAs. The multiple targeting sites of a single drug also increase the local concentration of the drug, thereby improving the binding effect with the targeted miRNA.

[0156] Preparation of single-stranded circular RNA:

[0157] Step 1: Circ-1, circ-2, circ-3, circ-4, DNA-1, DNA-2, and DNA-3 were mixed in equal amounts at a concentration of 10 μmol / L in 1×TAE-12.5 mmol / L magnesium acetate buffer. The mixture was incubated at 70°C for 5 minutes and then cooled at a rate of 0.5°C / min to 4°C.

[0158] Step 2: Treat the assembly mixture with T4 RNA Ligase 2 and incubate at 37°C for 10 h. Desalt the mixture by ultracentrifugation in RNase-free ddH2O at room temperature using a 3 kDa molecular weight cutoff ultrafiltration tube.

[0159] Step 3: The above solution was concentrated to a fixed concentration and mixed with an equivalent amount of cycle-1 at a concentration of 1 μmol / L in 1×TAE-12.5 mmol / L magnesium acetate buffer. After incubation at 70°C for 5 minutes, the temperature was gradually decreased at a rate of 0.5°C / min to 4°C.

[0160] Step 4: Then treat with circligase and keep at 45°C for 2 hours to obtain single-stranded circular RNA.

[0161] Step 5: Digest the DNA fragments and linear RNA fragments in the system with DNase I and RNase R. Finally, precipitate with ethanol to enrich the target product.

[0162] Characterization test of single-stranded circular RNA:

[0163] Polyacrylamide gel electrophoresis characterization: 10% (19:1) polyacrylamide gel and sample solution mixed with formamide at a ratio of 1:1 were prepared separately. The sample was loaded in 1×TBE buffer at 50°C and the gel was run at a voltage of 200V.

[0164] Synthesis and purification characterization are shown in Figure 2. Band 4 in the left image demonstrates that after circligase treatment, the yield of single-stranded circular RNA reaches over 60%. Band 3 in the right image demonstrates that DNase I treatment completely degrades DNA fragments, while band 4 demonstrates that RNase R treatment further degrades linear RNA fragments, thereby enriching single-stranded circular RNA products.

[0165] Example 2 Preparation of 254 nt single-stranded circular RNA with precise site Ψ (pseudouridine) modification

[0166] Preparation of single-stranded circular RNA with precise site-specific Ψ modification:

[0167] Step 1: RNA fragments of circ-1, circ-2, circ-3, and circ-4 with Ψ modifications and DNA-1, DNA-2, and DNA-3, the same DNA fragments as in Example 1, were mixed at a concentration of 10 μmol / L in 1×TAE-12.5 mmol / L magnesium acetate buffer. The mixture was incubated at 70°C for 5 minutes and then cooled at a rate of 0.5°C / min to 4°C.

[0168] A 254 nt single-stranded circular RNA with precise site Ψ modification was prepared using the method described in steps 2-5 of Example 1. The specific modification sites are shown in Figure 4.

[0169] Functional validation of circRNAs with precise site-specific Ψ modifications as miRNA sponges

[0170] The functional characterization of the modified single-stranded circular RNA was performed using the functional verification experimental method of the single-stranded circular RNA as a miRNA sponge in Example 3.

[0171] The experimental results (Figure 5) show that the Ψ modification does not affect the ability of the single-stranded circular RNA to adsorb the targeted miRNA. In particular, at low concentrations, it can achieve the same effect as unmodified single-stranded circular RNA and miRNA complementary short strands.

[0172] Characterization of the immunogenicity of single-stranded circular RNA with precise site-specific Ψ modification

[0173] The immunogenicity of the modified circRNA was characterized using the immunogenicity characterization experimental method of single-stranded circular RNA in Example 3.

[0174] The experimental results (Figure 6) show that unmodified single-stranded circular RNA is highly immunogenic, leading to overexpression of cytokines such as IFN-β, IL-6, CCL-2, TNF-α, and IL-1β. Introducing a certain proportion of Ψ modification significantly reduced cytokine expression, with immunogenicity being significantly reduced with just a 30% modification ratio.

[0175] Example 3: Functional verification of single-stranded circular RNA as a miRNA sponge

[0176] MCF-7 cells were cultured to the logarithmic growth phase, and the single-stranded circular RNA obtained in Examples 1 and 2 was transfected into the cells using Messenger Max for co-culture. Cell viability and the expression level of the gene targeted by the single-stranded circular RNA in the cells were detected. The specific steps are as follows:

[0177] Step 1: MCF-7 adherent cells were routinely cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (Gibco, final concentrations of 100 units / mL penicillin and 100 μg / mL streptomycin) in a 5% CO2 incubator at 37°C.

[0178] Step 2: Cells were plated in a 96-well plate at 8,000 cells per well. 100 μL of DMEM medium containing 10% fetal bovine serum was added. After 12 hours of culture, the single-stranded circular RNA obtained in Example 1 and Example 2 and the dual-luciferase reporter gene plasmid were co-transfected into the cells using Messenger Max transfection reagent at a final concentration of 20 nmol / L. A blank control group was treated with an equal volume of PBS.

[0179] Step 3: After 24 hours of cell culture, the cells were treated with a dual-tube luciferase reporter gene assay kit and analyzed using a microplate reader. The expression level of the targeted gene was detected by comparing the intensities of the two chemiluminescence signals ( FIG. 3 ).

[0180] Step 4: Perform cell viability assays after transfecting only the single-stranded circular RNA (ssRNA) in Step 2. After 24, 48, 72, and 120 hours of cell culture, add 10 μl of MTS reagent to each 96-well plate. Return the plate to the incubator and incubate for 1 hour. Then, use a microplate reader to measure absorbance at 450 nm and 690 nm (Figure 3).

[0181] In the adsorption experiment of targeted miRNA, for three miRNAs, compared with the miRNA complementary short chain (positive reference), single-stranded circular RNA showed better anti-miRNA effect at lower concentrations. This is specifically manifested in the effect of improving the expression of the miRNA-targeted luciferase reporter gene. In the cell activity test experiment, compared with the control group without drugs, the addition of single-stranded circular RNA and miRNA complementary short chain (positive reference) can inhibit the rate of cell proliferation, among which single-stranded circular RNA has a more obvious effect. On a time scale of 5 days, the inhibition efficiency can reach 50%.

[0182] Characterization of immunogenicity of single-stranded circular RNA

[0183] RAW264.7 cells were cultured to the logarithmic growth phase, and the single-stranded circular RNA obtained in Examples 1 and 2 was transfected into the cells using Messenger Max and co-cultured to detect the immunogenicity of the circular RNA. The specific steps are as follows:

[0184] Step 1: RAW264.7 adherent cells were routinely cultured using DMEM supplemented with 10% fetal bovine serum in a 5% CO2 incubator at 37°C.

[0185] Step 2: Cells were plated in a 12-well plate at 300,000 cells per well. 1 mL of DMEM medium containing 10% fetal bovine serum was added. After 12 hours of culture, the single-stranded circular RNAs obtained in Examples 1 and 2 were transfected into the cells using Messenger Max transfection reagent at a final concentration of 20 nmol / L. A blank control group was treated with an equal volume of PBS.

[0186] Step 3: After culturing the cells for 6 hours, use an RNA extraction kit to treat the cells and extract total RNA from the cells.

[0187] Step 4: Total RNA was processed using a reverse transcription-qPCR kit to characterize the expression levels of different cytokines, thereby comparing the immunogenicity of differently modified single-stranded circular RNAs (Figure 6).

[0188] The results showed that unmodified single-stranded circular RNA had high immunogenicity and could lead to overexpression of cytokines such as IFN-β, IL-6, CCL-2, TNF-α and IL-1β.

[0189] References

[0190] [1]Bajan S,Hutvagner G.RNA-Based Therapeutics:From Antisense Oligonucleotides to miRNAs[J].Cells,2020,9(1).

[0191] [2]Rinaldi C,Wood M J A.Antisense oligonucleotides:the next frontier for treatment of neurological disorders[J].Nature Reviews Neurology,2018,14(1):9-21.

[0192] [3]Statello L,Guo C-J,Chen L-L,et al.Gene regulation by long non-coding RNAs and its biological functions[J].Nature Reviews Molecular Cell Biology,2021,22(2):96-118.

[0193] [4]Adachi T,Nakamura Y.Aptamers:A Review of Their Chemical Properties and Modifications for Therapeutic Application[J].Molecules,2019,24(23).

[0194] [5]Micura R, C.Fundamental studies of functional nucleic acids:aptamers,riboswitches,ribozymes and DNAzymes[J].Chemical Society Reviews,2020,49(20):7331-7353.

[0195] [6]Müller S,Wedler A,Breuer J,et al.Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in mice[J].NAR Cancer,2020,2(3):zcaa014.

[0196] [7]Lavenniah A,Luu T D A,Li Y P,et al.Engineered Circular RNA Sponges Act as miRNA Inhibitors to Attenuate Pressure Overload-Induced Cardiac Hypertrophy[J].Molecular Therapy,2020,28(6):1506-1517.

[0197] [8]Liu X,Abraham J M,Cheng Y,et al.Synthetic Circular RNA Functions as a miR-21 Sponge to Suppress Gastric Carcinoma Cell Proliferation[J].Mol Ther Nucleic Acids,2018,13:312-321.

[0198] [9]Marie Flamme,Luke K McKenzie,Ivo Sarac,et al.Chemical methods for the modification of RNA[J].Methods,2019,161:64-82.

Claims

1. A nucleic acid combination comprising at least 2 first RNA fragments, at least 2 first DNA fragments, and optionally, at least 1 second DNA fragment; wherein The first RNA fragment comprises a 5' spacer region, a functional sequence region and a 3' spacer region; the first RNA fragment is used to connect to form a long single-stranded RNA; The first DNA fragment comprises a sequence complementary to the 5' spacer region of the first RNA fragment and a sequence complementary to the 3' spacer region of another first RNA fragment; The second DNA fragment comprises a sequence that is completely or partially complementary to the sequence at the 5' end of the long single-stranded RNA, and a sequence that is completely or partially complementary to the sequence at the 3' end of the long single-stranded RNA. 2 . The nucleic acid combination according to claim 1 , wherein the first RNA fragment comprises a 5′ spacer region, a functional sequence region and a 3′ spacer region from the 5′ end to the 3′ end. 3 . The nucleic acid combination according to claim 1 , wherein the first DNA fragment comprises a sequence that is completely or partially complementary to the 5′ spacer of the first RNA fragment and a sequence that is completely or partially complementary to the 3′ spacer of another first RNA fragment.

4. The nucleic acid combination according to claim 1, wherein the 5' spacer sequence of each first RNA fragment is different, the 3' spacer sequence of each first RNA fragment is different, and / or the 5' spacer sequence and 3' spacer sequence of the same first RNA fragment are different.

5. The nucleic acid combination according to claim 1, wherein the second DNA fragment comprises a sequence complementary to a 4-35 nt sequence at the 5' end of the long single-stranded RNA, and a sequence complementary to a 4-35 nt sequence at the 3' end of the long single-stranded RNA.

6. The nucleic acid combination according to claim 1, wherein the functional sequence region is a sequence that interacts with miRNA, short-chain RNA of 15-50 nt in length, mRNA, pre-mRNA, lncRNA, circRNA, DNA or protein. The nucleic acid combination according to claim 1 , wherein the length of the 5′ spacer and / or the 3′ spacer is 8-20 nt.

8. The nucleic acid combination according to claim 1, wherein the second DNA fragment is 32-80 nt in length, preferably 64 nt.

9. The nucleic acid combination according to claim 1, wherein the first RNA fragment has a length of 16-100 nt.

10. The nucleic acid combination according to claim 1, wherein the first DNA fragment is 16-40 nt in length. The nucleic acid combination according to claim 1 , wherein the number of the first RNA fragments is at most 20, preferably 4-10.

12. A method for preparing single-stranded circular RNA, comprising the following steps: Step (1): connecting the first RNA fragments according to any one of claims 1 to 11 to obtain a long single-stranded RNA; Step (2): Connect two long single-stranded RNAs to obtain single-stranded circular RNA.

13. The method according to claim 12, wherein the step (1) comprises the following steps: Step (1.1): mixing the first RNA fragment and the first DNA fragment according to any one of claims 1 to 11 and then annealing them; Step (1.2): connecting the product of step (1.1); Optionally, step (1.3): purifying the product of step (1.2).

14. The method according to claim 13, wherein step (1.2) uses T4 RNA ligase for ligation.

15. The method according to claim 13, wherein step (1.3) comprises an ultrafiltration step, optionally, purification is performed using an ultrafiltration tube operation or using size-sorting magnetic beads.

16. The method according to claim 13, wherein the step (2) comprises the following steps: Step (2.1): mixing the product of step (1) with the second DNA fragment according to any one of claims 1 to 11 and then annealing; Step (2.2): connecting the product of step (2.1); Optionally, step (2.3): purifying the product of step (2.2).

17. The method according to claim 16, wherein step (2.2) uses a circularizing ligase for ligation.

18. The method according to claim 16, wherein step (2.3) comprises the following steps: Step (2.3.1): Add DNaseI for enzyme digestion; Step (2.3.2): adding RNase R for digestion; and / or Step (2.3.3): Purification is optionally carried out using ethanol and using an ultrafiltration method.

19. The method according to claim 12, wherein the length of the single-stranded circular RNA is 180nt-1000nt, preferably 240nt-1000nt.

20. Use of the nucleic acid combination according to claim 1 in preparing single-stranded circular RNA, optionally, the first RNA fragment comprises RNA modification.

21. The single-stranded circular RNA according to the preceding claim, for use in treating, preventing or diagnosing a disease or in preparing a drug for treating or preventing a disease or a diagnostic or detection reagent.

22. The single-stranded circular RNA according to claim 21, which performs a regulatory function on a target nucleic acid in a subject; preferably regulates the function of pre-mRNA, mRNA, miRNA, LncRNA, circRNA and tRNA in a subject.

23. The single-stranded circular RNA according to claim 22, which can be used as a sponge for RNA drugs, preferably the RNA drugs are miRNA drugs and / or siRNA drugs.

24. Use of a second DNA fragment for preparing a single-stranded circular RNA, the second DNA fragment comprising a sequence complementary to the sequence at the 5' end of the long single-stranded RNA according to the preceding claim, and a sequence complementary to the sequence at the 3' end of the long single-stranded RNA according to the preceding claim.

25. The use according to claim 24, wherein the 5' and 3' end sequences of the second DNA fragment comprise sequences that are completely or partially complementary to the 5' end sequence of the long single-stranded RNA according to the preceding claim.

26. The use according to claim 24, wherein the non-5'-non-3' sequence of the second DNA fragment comprises a sequence that is completely or partially complementary to the 3'-end sequence of the long single-stranded RNA according to the preceding claim.

Citation Information

Patent Citations

  • Circular RNA (ribonucleic acid) with molecular marker as well as preparation method and application thereof

    CN106834293A

  • Single-chain ring-shaped nucleic acid as well as preparation method and application thereof

    CN109161572A

  • Method for large-scale synthesis of long-chain RNA and method for fixed-point modification of long-chain RNA

    CN111235198A

  • Preparation method of single-stranded circular DNA

    CN111793619A

  • Method for preparing long-chain RNA modified at specific site

    WO2022170705A1

Cited By

  • Efficient RNA enzymatic ligation method

    WO2026002219A1